Advice

following a full submission assessed under the end of life and orphan medicine process:

encorafenib (Braftovi®) is not recommended for use within NHSScotland.

Indication under review: In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Progression-free survival was significantly longer in the encorafenib plus binimetinib group compared with BRAF inhibitor monotherapy in a phase III study of patients with unresectable or metastatic BRAF V600 melanoma.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
encorafenib (Braftovi)
SMC ID:
SMC2145
Indication:

encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

Pharmaceutical company
Pierre Fabre Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Not recommended
Date advice published:
08 July 2019